President Trump sent letters Thursday to 17 of the world’s largest drug companies, telling them to take more steps to slash ...

Early-onset GI cancers diagnosed before age 50 are rising at alarming rates worldwide, underscoring the need for enhanced ...

In letters to the companies released on Thursday, Trump said he expected them to deliver on a series of measures to lower ...

The remainder of 2025 will be busy for Vir Biotechnology as it strives to successfully pivot to developing cancer and infectious disease therapies.

GlaxoSmithKline ( ($GSK) ) has released its Q2 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors.

British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, ...

A single dose of RSVPreF3 OA offered protection against RSV-related lower respiratory tract disease across three RSV seasons ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

With the stock's last traded price at Rs 3,081, GlaxoSmithKline Pharmaceuticals has experienced a notable decline, positioning it among the top losers on the Nifty Midcap 150 index.

The global chicken pox market is experiencing significant growth driven by the widespread prevalence of the varicella-zoster virus, low vaccination r ...